Lazarex will be recognized on the evening of Wednesday, June 5, 2013 at the Westin Boston Waterfront
DANVILLE, Calif., April 23, 2013 /PRNewswire/ — Lazarex Cancer Foundation has been selected as part of this year's "The One Hundred" by Massachusetts General Hospital Cancer Center. Mass General Cancer Center picks 100 individuals and groups whose diligence and discoveries, philanthropy and passion have helped advance the fight against cancer. Past honorees have included doctors, nurses, researchers, philanthropists and Nobel laureates, as well as those who run marathons to raise money, have started foundations and advocacy organizations, and have baked cookies for patients!
Lazarex Cancer Foundation's dedication to the improvement of cancer care is extraordinary, and the reason they were chosen as one of "The One Hundred." The foundation's commitment to cancer care will be recognized at this year's event at the Boston Waterfront on Wednesday, June 5, 2013. The evening program will highlight a selection of honoree stories as well as speakers from Mass General Cancer Center. Funds raised at the event will support the Cancer Center's patient care, research, education and community outreach programs. For more information, visit the website http://theonehundred.org.
Lazarex supports cancer patients who want to participate in FDA clinical trials by providing assistance with costs for clinical trial participation and navigation through clinical trial options. The foundation also provides community outreach and educational services. Lazarex was formed as a nonprofit in 2006 by Dana Dornsife after her brother-in-law developed pancreatic cancer. Clinical trials are frequently the last hope for cancer patients, and Lazarex's mission is to help patients keep their dignity and hope alive while undergoing treatment.
"The good news is that we have been very successful in raising our profile with potential patients, and the further good news is that our patients are living longer and generating greater hope through the success of the clinical trials we have helped them find," Dornsife said. "As a result we have to broaden our appeal for donations to help defray the costs incurred as out-of-pocket expenses by our patients who usually travel great distances to participate in the clinical trials."
Those interested in helping Lazarex extend the gift of hope can do so by visiting its website at www.lazarex.org. Visitors can not only make a straight donation, they can also explore the various events Lazarex holds and the products it sells to mix in some fun with their giving.
For further information on Lazarex, check out www.lazarex.org.
Kirk Meyer
Webworks Press Services
831 419 7875
Email